Please rotate your device

GET PROPEL

Stay Informed

    Stay informed

    Sign up for the PROPEL mailing list

    Provide some basic information and we’ll send you relevant content and event reminders.




    • ENT/Rhinologist
    • Other

    *ALL FIELDS REQUIRED

    By providing the above information, you agree to allow Intersect ENT to provide you with information relating to Intersect ENT’s products. The information you submit will be governed by our Privacy Policy.

      GET PROPEL

      SIGN UP TO GET PROPEL

      Empower your practice with PROPEL. Provide some basic information to connect to a representative.




      • ENT/Rhinologist
      • Other

      *ALL FIELDS REQUIRED

      By providing the above information, you agree to allow Intersect ENT to provide you with information relating to Intersect ENT’s products. The information you submit will be governed by our Privacy Policy.

      You are leaving the HCP website

      You are being directed to a third-party website. Please note that this third-party website is not controlled by PROPELOpens.com.

      Thank you for visiting our site.

      Continue

      6 REASONS TO ADD THE PROPEL FAMILY OF IMPLANTS TO YOUR SINUS SURGERY ARMAMENTARIUM

      Provides your sinus surgery patients with individualized treatment options1-3

      • Intersect ENT has a complete portfolio of implants indicated for use following ESS
      • Intersect ENT offers a family of 3 steroid-eluting implants under one brand: PROPEL
      • The PROPEL family of steroid-eluting implants provides you with the flexibility to treat different sinus anatomies, including the ethmoid, maxillary, and frontal sinuses in a multitude of patient types
      • PROPEL implants promote a tailored approach to postoperative care with options on implants’ indication, size, shape, and delivery system
      • The PROPEL implant provides localized delivery of mometasone furoate (MF), minimizing the reliance of patient compliance

      ESS, endoscopic sinus surgery.

      Breakthrough technology that opens the sinus cavity and delivers mometasone furoate1-3

      • PROPEL implants feature an innovative 2-in-1 mechanism that opens the sinuses while delivering mometasone furoate, an advanced corticosteroid, directly where it is needed
      • Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics: highly lipophilic, targeted and potent, and low systemic bioavailability
      • PROPEL implants are composed of a bioabsorbable polymer that breaks down between 30-45 days so implant removal is not required
      • PROPEL has a non-obstructive self-expanding design that allows for mucociliary clearance and the delivery of topical rinses

      Delivers the power of robust, clinically proven benefits1-3

      • The efficacy and safety profiles were established in over 350 patients enrolled across 6 clinical studies
      • Proven in prospective randomized, blinded, intra-patient controlled trials to reduce

      PROPEL

      • the need for postoperative interventions
      • the need for surgical interventions
      • the need for oral steroids
      • frank polyposis
      • significant adhesions
      • middle turbinate lateralization
      • patients’ perceived burden of symptoms

      PROPEL Mini

      • the need for postoperative interventions
      • the need for surgical interventions
      • the need for oral steroids
      • occlusion/restenosis

      PROPEL Contour

      • the need for postoperative interventions
      • the need for surgical interventions
      • occlusion/restenosis
      • inflammation
      • PROPEL in the ethmoid is proven to positively impact patients’ perceived burden of symptoms at 6 months

      Proven success in the real world1-6

      • With more than 7 years of real-world use and over 300,000 patients treated, the trusted performance of PROPEL family of implants provide patients with proven improvements in sinus surgery outcomes
      • Supported by Level 1-A evidence to significantly improve outcomes of ethmoid sinus surgery
      • First and only FDA-approved steroid-eluting sinus implant
      • PMA-approved
      • 15+ peer-reviewed publications

      Efficacious regardless of disease severity4

      PROPEL demonstrated efficacy across multiple patient types:

      • With and without nasal polyps
      • Undergoing primary and revision surgery
      • Undergoing traditional and ballooning surgery

      Intersect ENT partnership and collaboration

      • One of the only companies specifically dedicated to innovation in the field of otolaryngology
      • Dedicated to improving the quality of life for patients with ENT conditions providing robust clinical evidence
      • Continued collaboration with physicians to innovate and transform CRS care

      CRS, chronic rhinosinusitis.

      Complete your in-office
      arsenal with PROPEL

      Watch Dr. Matheny discuss the postoperative use of PROPEL in the office, following a bilateral ethmoidectomy in an ambulatory surgery center

      HISTORY AND PRESENTING SYMPTOMS*

      • Long history of CRS without nasal polyps and allergic rhinitis

      • Maximally managed with daily allergy medication, immunotherapy, antibiotics (5-6 times per year), and oral steroids (3-4 times per year)

      • Continued to suffer from nasal obstruction, facial pain and pressure, periorbital headache, changes to taste and smell, and nasal drainage

      • Underwent total bilateral ethmoidectomy with concurrent balloon catheter dilation of the frontal and maxillary sinus outflow tracts, in an ambulatory surgery setting

      • In this ambulatory surgery setting, the patient did not have access to PROPEL

      • Next steps: Postoperative PROPEL placement in the office

      *This case is intended for general medical education purposes only and is not a substitute for independent clinical medical judgment.
      Response to treatment may vary from patient to patient.

      PROPEL FITS WITHIN YOUR IN-OFFICE PRACTICE

      Improve sinus surgery outcomes for your patients with CRS by offering PROPEL implants in your in-office practice through a two-pronged approach: in-office sinus procedures or postoperatively.

      PROPEL
      IN-OFFICE
      IMPLANT
      OPTIONS

      1

      IN-OFFICE SINUS PROCEDURES

      Implants following in-office ESS such as balloon sinus dilation

      2

      POSTOPERATIVE UTILIZATION

      Implants during the postoperative healing period after sinus surgery

      • CLINICAL APPLICATION

      • Intended for use following sinus surgery to maintain patency, thereby reducing the need for postoperative surgical intervention and use of oral steroids1-3
      • Separate mucosal tissues, provide stabilization of the middle turbinate, prevent obstruction by adhesions, and reduce edema/inflammation1-3
      • Innovative 2-in-1 technology that opens the sinuses while delivering mometasone furoate directly where it is needed1-3

      • COVERAGE

      • Positive coverage and access with commercial payors, such as UnitedHealthCare, Blue Cross Blue Shield FEP, and HCSC*†
      • Positive coverage and access with government payors, such as VA, TriCare, and select Medicare plans*†
      • Billing a CPT code for in-office use of PROPEL implants is applicable

      • VALUE TO YOUR PRACTICE

      • Easily loaded; fast and precise deployment
      • Innovative technology for your patients with CRS, with tools to facilitate patient outreach
      • Dedicated team to assist with payor coverage and reimbursement
      • Tailored care for your patients with PROPEL implants: Implants of varying sizes and shapes indicated to treat the frontal, maxillary, and ethmoid sinuses1-3

      Actor portrayal with simulated endoscopy.

      CPT, current procedural terminology; ESS, endoscopic sinus surgery; FEP, federal employee program; HSCS, Health Care Service Corporation; VA, Veterans Affairs.

      *Coverage information as of September 2020
      †DISCLAIMER: This is not a guarantee of payment, coverage, or reimbursement. Individual payer plans may vary.

      Arm yourself with PROPEL in the office

      MORE THAN 7,000 PATIENTS TREATED IN THE OFFICE SINCE 20117

      Choose from 3 steroid-eluting implants under one brand to select the best option that conforms to the anatomical needs of your patients.

      The following information is for processing and payment for sinus implants when used in the non-facility setting:

      HCPCS

      J7401

      DESCRIPTION

      Mometasone furoate sinus implant, 10 micrograms

      BILLABLE UNITS

      10 micrograms = 1 unit billed

      SITE OF SERVICE

      11 (In-office)

      For unilateral placement of a drug-eluting sinus implant, report 37 units (370 mcgs/10 = 37 units)

      For bilateral placement of a drug-eluting sinus implant, report 74 units (370 mcgs x 2 = 740/10 = 74 units)

      ETHMOID SINUS

      PROPEL MINI (NDC: 10599-0001-01)

      PROPEL (NDC: 10599-0000-01)

      FRONTAL SINUS OSTIA

      PROPEL MINI (NDC: 10599-0001-01)

      PROPEL CONTOUR (NDC: 10599-0002-01)

      MAXILLARY SINUS OSTIA

      PROPEL CONTOUR (NDC: 10599-0002-01)

      PROPEL implants were evaluated in clinical trials that included patients with and without nasal polyps, undergoing primary or revision surgery by traditional instrumentation or ballooning procedures5

      YOUR PATIENTS + PROPEL = IMPROVED OUTCOMES

      GET PROPEL

      Stay Informed

      This site is intended for healthcare professionals in the United States

      Instructions for Use:

      PROPEL PROPEL MINI PROPEL MINI WITH SDS PROPEL Contour

      Instructions for Use (EU):

      PROPEL PROPEL MINI
      Stay Informed

      References

      1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
      2. ROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
      3. PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
      4. Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
      5. Data on file, Intersect ENT, Inc. Calculated Patients – PROPEL Family. Q2 2019.
      6. Food and Drug Administration. Approval Order. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044S018A.pdf. Accessed June 28, 2019.
      7. Data on file. Intersect ENT, Inc. Through Q3 2020.

      The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

      Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

      The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/foreign patents, found at intersectent.com/patents.

      ©2021 Intersect ENT, Inc. All rights reserved. MPM-11549 Rev 4.0